Ontology highlight
ABSTRACT:
SUBMITTER: Kaplan FM
PROVIDER: S-EPMC6591715 | biostudies-literature | 2011 Jan
REPOSITORIES: biostudies-literature
Kaplan F M FM Shao Y Y Mayberry M M MM Aplin A E AE
Oncogene 20100906 3
Activating mutations in B-RAF and N-RAS occur in ∼60 and ∼15% of melanomas, respectively. The most common mutation in B-RAF is V600E, which activates B-RAF and the downstream MEK-ERK1/2 pathway. Thus, B-RAF(V600E) is a viable therapeutic target. PLX4720 is a selective inhibitor of mutant B-RAF and its analog, PLX4032, is currently undergoing clinical trials in melanoma. However, the effects of PLX4720 across the genotypic spectrum in melanoma remain unclear. Here, we describe that PLX4720 treatm ...[more]